Close this search box.

The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer’s disease isn’t worth its cost. But the economists omit several key considerations about the devastating neurodegenerative disease.

View Graphic

Leave a Reply

Your email address will not be published. Required fields are marked *